Annals of nuclear medicine · 2025
Feasibility of targeted alpha therapy for Alzheimer's disease using 211At-labeled agent targeting amyloid-β aggregates.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kashiyama Rikuto, Watanabe Hiroyuki, Akasaka Takahiro, Fujimoto Hiroyuki, Murakami Masashi, Ooe Kazuhiro, Toyoshima Atsushi, Nakashima Kazuma, Ono Masahiro
Аннотация
OBJECTIVE: Amyloid-β (Aβ) aggregates have been recognized as therapeutic targets for Alzheimer's disease (AD). Targeted alpha therapy (TAT) using α-particles has the potential to be applied as a novel treatment approach for AD by reducing the quantity of Aβ aggregates. In this study, we developed a novel astatine-211-labeled pyridyl benzofuran (PBF) derivative, [211At]APBF-2, as a small molecule-based Aβ-TAT agent and evaluated its potential for in vivo use.
METHODS: [211At]APBF-2 was synthesized in a one-step astatination process using the tributyltin precursor. In the Aβ aggregation inhibition assay, [211At]APBF-2 was added to a sample containing Aβ1-42 monomers and thioflavin-T (ThT) and the mixture was incubated for 24 h. The quantity of Aβ aggregates was evaluated by measuring ThT fluorescence intensity. The biodistribution of [211At]APBF-2 (25 kBq/100 μL) was evaluated using ddY mice (n = 5).
RESULTS: [211At]APBF-2 was synthesized in radiochemical yield of 57% with a radiochemical purity of over 95%. In the in vitro assay, [211At]APBF-2 showed a dose-dependent decrease in ThT fluorescence intensity, suggesting the ability of [211At]APBF-2 to inhibit Aβ aggregation. In the biodistribution study using normal mice, the initial brain uptake of [211At]APBF-2 was observed (2.95% injected dose/g at 2 min), demonstrating favorable Blood-brain barrier permeability.
CONCLUSIONS: These results suggest the feasibility of using [211At]APBF-2 as an Aβ-TAT agent for in vivo applications.
METHODS: [211At]APBF-2 was synthesized in a one-step astatination process using the tributyltin precursor. In the Aβ aggregation inhibition assay, [211At]APBF-2 was added to a sample containing Aβ1-42 monomers and thioflavin-T (ThT) and the mixture was incubated for 24 h. The quantity of Aβ aggregates was evaluated by measuring ThT fluorescence intensity. The biodistribution of [211At]APBF-2 (25 kBq/100 μL) was evaluated using ddY mice (n = 5).
RESULTS: [211At]APBF-2 was synthesized in radiochemical yield of 57% with a radiochemical purity of over 95%. In the in vitro assay, [211At]APBF-2 showed a dose-dependent decrease in ThT fluorescence intensity, suggesting the ability of [211At]APBF-2 to inhibit Aβ aggregation. In the biodistribution study using normal mice, the initial brain uptake of [211At]APBF-2 was observed (2.95% injected dose/g at 2 min), demonstrating favorable Blood-brain barrier permeability.
CONCLUSIONS: These results suggest the feasibility of using [211At]APBF-2 as an Aβ-TAT agent for in vivo applications.